Although it remains to be ascertain whether the decrease of circulating PTTG1 in responder patients simply reflects the reduction of tumor burden or is also due to drug-induced down-regulation of PTTG1 expression in melanoma cells, these findings are consistent with and reinforce our in vitro results. The gene discussed is PTTG1; the disease is neoplasm.